newsfilter
← Latest News
GlobeNewswire·

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

RNXT
  • RenovoRx, Inc. (NASDAQ: RNXT) CEO Shaun Bagai & CFO Mark Voll will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.
  • Management will discuss record second-quarter 2026 revenue driven by commercial demand for RenovoCath & strong repeat orders from high-volume cancer centers.
  • The presentation will highlight the first clinical use of RenovoCath in a sarcoma patient at CARTI Cancer Center Little Rock, indicating potential for broader solid tumor treatment.
  • CEO Bagai will provide an update on the fully enrolled Phase III TIGeR-PaC trial, which expects completion in the first half of 2027 & initial top-line data in the second half of 2027.
  • August 2026 PK-PD data from a TIGeR-PaC sub-study showed TAMP-mediated delivery concentrated chemotherapy at the tumor site, extracting 51% locally & correlating with lower CA 19-9 levels.
  • Bagai will cover investigator-initiated trials (IITs) for borderline resectable & metastatic pancreatic cancer, along with an ongoing post-marketing registry study to expand clinical evidence for the TAMP platform.
  • RenovoRx generated approximately $1.1 million in RenovoCath sales in 2025 & achieved record quarterly revenue of $909,000 in Q2 2026.
  • The IAG product candidate (intra-arterial gemcitabine via RenovoCath) is under FDA investigation via an IND application, with Orphan Drug Designation received for pancreatic & bile duct cancers.
  • The conference presentation is scheduled for Monday, September 14 at 1:30 p.m. ET in the Louis room (4th Floor) with a webcast available at the investor relations website.